Print this page
Monday, 25 March 2013 13:22

First cancer drug with a virus is created

Rate this item
(1 Vote)

clinical trails dna rna monoclonal antibody targattMedicine for the treatment of cancer based on a virus destroying tumor cells for the first time successfully passed clinical trials in advanced stage, said U.S. pharmaceutical manufacturer Amgen.

A statement from the company product has achieved the main objective of the Phase III clinical trial in patients with advanced melanoma - the most aggressive type of skin cancer. The results showed that 16% of patients who received treatment had a significant tumor poured lasting six months or more, compared with only 2% of the control group.

A spokesman for the company declined to say whether the company will apply for registration to the FDA on the basis of this study.

It contains the virus Talimogene laherparepvec, genetically modified in a way that causes him to multiply only in rapidly growing cells. The product is injected directly into the tumor, after which the virus enters the cancer cells and causes them to synthesize large amounts of granulocyte-monocyte colony stimulating factor - the hormone that stimulates the maturation of immune cells. When cancerous cells die, they release new amounts of virus and acquired therein colony stimulating factor, which boost the immune system.

The study was conducted in 400 patients, two thirds of whom received injections every two weeks. The rest of the participants received injections only granulocyte-monocyte colony stimulating factor. According to Dr. Anthony Ribas, melanoma specialist at the University of Los Angeles, the study results are positive, but it is uncertain whether sufficient authorization for use.

Read 3161 times

Related items